In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Antimicrobial Agents and Chemotherapy Year : 2008

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors.

Abstract

We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir. Saquinavir, lopinavir, and darunavir are potent against wild-type HIV-2 isolates and should be preferred as first-line options for HIV-2-infected patients. Other protease inhibitors are less active against HIV-2 than against HIV-1.
Fichier principal
Vignette du fichier
Desbois.pdf (96.07 Ko) Télécharger le fichier

Dates and versions

inserm-00263591 , version 1 (12-03-2008)

Identifiers

Cite

Delphine Desbois, Bénédicte Roquebert, Gilles Peytavin, Florence Damond, Gilles Collin, et al.. In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors.. Antimicrobial Agents and Chemotherapy, 2008, 52 (4), pp.1545-1548. ⟨10.1128/AAC.01284-07⟩. ⟨inserm-00263591⟩
203 View
307 Download

Altmetric

Share

Gmail Facebook X LinkedIn More